HCWB is trading 6.6% up today at $1.30 after swinging to a rare Q1 profitability driven by a $6.5 million licensing deal with Beijing Trimmune Biotech.
- The company reported net income of $3.47 million, fueling a sharp multi-day rally and significant event-driven momentum.
- Despite the profit, the firm continues to face going-concern risks and a potential NASDAQ delisting related to minimum bid price compliance.